US › Healthcare

Xenetic Biosciences Inc (XBIO)

US · Healthcare · Biotechnology

$1.99-1.00%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$660,601

Revenue YoY

+12.0%

Net profit

$-929,695

EPS

$-0.41

Net margin

-140.7%

Key statistics

Market cap

$4.9M

Forward P/E

0.0

P/B

0.96

Book value

$2.59

EPS (TTM)

$-1.15

52-week high

$4.94

52-week low

$1.87

50-day MA

$3.17

200-day MA

$2.86

Beta

2.20

Analyst view

with an average price target of $40.00.

Shareholding

Insiders

11.43%

Institutions

6.49%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	5.01%
Geode Capital Management, LLC	0.74%
Vanguard Capital Management, LLC	0.54%
JTC Employer Solutions Trustee Ltd	0.12%
SBI Securities Co Ltd	0.04%
Tower Research Capital LLC	0.03%
Morgan Stanley - Brokerage Accounts	0.01%
Harwood Advisory Group, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xenetic Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.